In order to confirm that our OVA-DC10 were also tolerogenic in vivo, we used them to treat mice in which we had induced an asthma phenotype, and here too OVA-presenting DC10 significantly down-regulated 2 dy airway Th2 (i.e., IL-4, IL-5 and IL-13) responses to recall allergen challenges issued at 3 wk after DC10 immunotherapy (Fig 1C). This evidence concerns the gene IL4 and asthma.